Endologix Announces Release Date for Third Quarter 2016 Financial Results and Details of 2016 Investor Meeting

IRVINE, Calif., Oct. 24, 2016 -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its third quarter 2016 financial results, which will take place on Tuesday, November 1, 2016 after the close of the market, and its 2016 Investor Meeting, which will take place November 17, 2016 at the Sheraton New York Times Square Hotel in New York City. 

Third Quarter 2016 Conference Call Information
Endologix will hold a conference call on Tuesday, November 1, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the financial results of the third quarter 2016. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.

After the live webcast, a replay of the webcast will remain available online from the investor relations page of Endologix's website, www.endologix.com, through November 1, 2017. In addition, a transcript will be posted to website and a telephonic replay of the call will be available until November 8, 2016. The replay dial-in numbers are (844) 512-2921 for domestic callers and (412) 317-6671 for international callers.  Please use the replay pin number 13648565.

2016 Investor Meeting
Endologix will hold its 2016 Investor Meeting on November 17, 2016 from 4:30 to 7:00 pm ET at the Sheraton New York Times Square Hotel in New York City. The event will include a Company update along with presentations from prominent physicians on the Company’s product portfolio and a question and answer session with the physicians and Endologix management.

A live audio webcast of the investor meeting will be available by visiting the investor relations section of Endologix's website at www.endologix.com. Participants are encouraged to log on a few minutes prior to 5:00 pm ET in order to download any applicable audio software. A replay of the presentation will be available within 24 hours and will be available for approximately one year.

Please RSVP by contacting Brandon Vazquez at The Ruth Group at: [email protected] or 646-536-7032 by November 14, 2016.

About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

ENDOLOGIX CONTACT:
Endologix, Inc.
John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020